Selected research
Industry Research
Hydroxychloroquine for COVID-19 Industry Research Report 2026
Market perspective
The global Hydroxychloroquine for COVID-19 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Hydroxychloroquine for COVID-19 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Hydroxychloroquine for COVID-19 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Hydroxychloroquine for COVID-19 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Hydroxychloroquine for COVID-19 include Advanz Pharma, Apotex, Bristol Laboratories, Hanlim Pharmaceutical, Ipca Laboratories, Kyung Poong, Sun Pharma, Zydus Cadila and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Hydroxychloroquine for COVID-19 market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hydroxychloroquine for COVID-19 Market by Company
Advanz Pharma
Apotex
Bristol Laboratories
Hanlim Pharmaceutical
Ipca Laboratories
Kyung Poong
Sun Pharma
Zydus Cadila
Mylan
Novartis
Sanofi
Shanghai Zhongxisanwei
Teva
Hydroxychloroquine for COVID-19 Segment by Type
Tablet
Injection
Hydroxychloroquine for COVID-19 Segment by Application
Mild Symptom Patient
Critically Ill Patient
Hydroxychloroquine for COVID-19 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hydroxychloroquine for COVID-19 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hydroxychloroquine for COVID-19 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hydroxychloroquine for COVID-19.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hydroxychloroquine for COVID-19 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hydroxychloroquine for COVID-19 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hydroxychloroquine for COVID-19 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablet
- Injection
Applications
- Mild Symptom Patient
- Critically Ill Patient
Companies covered
- Advanz Pharma
- Apotex
- Bristol Laboratories
- Hanlim Pharmaceutical
- Ipca Laboratories
- Kyung Poong
- Sun Pharma
- Zydus Cadila
- Mylan
- Novartis
- Sanofi
- Shanghai Zhongxisanwei
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hydroxychloroquine for COVID-19 Market Size (2021-2032)
- 2.2.2 Global Hydroxychloroquine for COVID-19 Sales (2021-2032)
- 2.2.3 Global Hydroxychloroquine for COVID-19 Market Average Price (2021-2032)
- 2.3 Hydroxychloroquine for COVID-19 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablet
- 2.3.3 Injection
- 2.4 Hydroxychloroquine for COVID-19 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Mild Symptom Patient
- 2.4.3 Critically Ill Patient
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hydroxychloroquine for COVID-19 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hydroxychloroquine for COVID-19 Sales (Tons) of Manufacturers (2021-2026)
- 3.3 Global Hydroxychloroquine for COVID-19 Revenue of Manufacturers (2021-2026)
- 3.4 Global Hydroxychloroquine for COVID-19 Average Price by Manufacturers (2021-2026)
- 3.5 Global Hydroxychloroquine for COVID-19 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hydroxychloroquine for COVID-19, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hydroxychloroquine for COVID-19, Product Type & Application
- 3.8 Global Manufacturers of Hydroxychloroquine for COVID-19, Established Date
- 3.9 Global Hydroxychloroquine for COVID-19 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Advanz Pharma
- 4.1.1 Advanz Pharma Company Information
- 4.1.2 Advanz Pharma Business Overview
- 4.1.3 Advanz Pharma Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Advanz Pharma Hydroxychloroquine for COVID-19 Product Portfolio
- 4.1.5 Advanz Pharma Recent Developments
- 4.2 Apotex
- 4.2.1 Apotex Company Information
- 4.2.2 Apotex Business Overview
- 4.2.3 Apotex Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Apotex Hydroxychloroquine for COVID-19 Product Portfolio
- 4.2.5 Apotex Recent Developments
- 4.3 Bristol Laboratories
- 4.3.1 Bristol Laboratories Company Information
- 4.3.2 Bristol Laboratories Business Overview
- 4.3.3 Bristol Laboratories Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol Laboratories Hydroxychloroquine for COVID-19 Product Portfolio
- 4.3.5 Bristol Laboratories Recent Developments
- 4.4 Hanlim Pharmaceutical
- 4.4.1 Hanlim Pharmaceutical Company Information
- 4.4.2 Hanlim Pharmaceutical Business Overview
- 4.4.3 Hanlim Pharmaceutical Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hanlim Pharmaceutical Hydroxychloroquine for COVID-19 Product Portfolio
- 4.4.5 Hanlim Pharmaceutical Recent Developments
- 4.5 Ipca Laboratories
- 4.5.1 Ipca Laboratories Company Information
- 4.5.2 Ipca Laboratories Business Overview
- 4.5.3 Ipca Laboratories Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Ipca Laboratories Hydroxychloroquine for COVID-19 Product Portfolio
- 4.5.5 Ipca Laboratories Recent Developments
- 4.6 Kyung Poong
- 4.6.1 Kyung Poong Company Information
- 4.6.2 Kyung Poong Business Overview
- 4.6.3 Kyung Poong Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kyung Poong Hydroxychloroquine for COVID-19 Product Portfolio
- 4.6.5 Kyung Poong Recent Developments
- 4.7 Sun Pharma
- 4.7.1 Sun Pharma Company Information
- 4.7.2 Sun Pharma Business Overview
- 4.7.3 Sun Pharma Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sun Pharma Hydroxychloroquine for COVID-19 Product Portfolio
- 4.7.5 Sun Pharma Recent Developments
- 4.8 Zydus Cadila
- 4.8.1 Zydus Cadila Company Information
- 4.8.2 Zydus Cadila Business Overview
- 4.8.3 Zydus Cadila Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zydus Cadila Hydroxychloroquine for COVID-19 Product Portfolio
- 4.8.5 Zydus Cadila Recent Developments
- 4.9 Mylan
- 4.9.1 Mylan Company Information
- 4.9.2 Mylan Business Overview
- 4.9.3 Mylan Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mylan Hydroxychloroquine for COVID-19 Product Portfolio
- 4.9.5 Mylan Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Hydroxychloroquine for COVID-19 Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 Sanofi
- 4.11.1 Sanofi Company Information
- 4.11.2 Sanofi Business Overview
- 4.11.3 Sanofi Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sanofi Hydroxychloroquine for COVID-19 Product Portfolio
- 4.11.5 Sanofi Recent Developments
- 4.12 Shanghai Zhongxisanwei
- 4.12.1 Shanghai Zhongxisanwei Company Information
- 4.12.2 Shanghai Zhongxisanwei Business Overview
- 4.12.3 Shanghai Zhongxisanwei Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Shanghai Zhongxisanwei Hydroxychloroquine for COVID-19 Product Portfolio
- 4.12.5 Shanghai Zhongxisanwei Recent Developments
- 4.13 Teva
- 4.13.1 Teva Company Information
- 4.13.2 Teva Business Overview
- 4.13.3 Teva Hydroxychloroquine for COVID-19 Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Teva Hydroxychloroquine for COVID-19 Product Portfolio
- 4.13.5 Teva Recent Developments
5 Global Hydroxychloroquine for COVID-19 Market Scenario by Region
- 5.1 Global Hydroxychloroquine for COVID-19 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hydroxychloroquine for COVID-19 Sales by Region: 2021-2032
- 5.2.1 Global Hydroxychloroquine for COVID-19 Sales by Region: 2021-2026
- 5.2.2 Global Hydroxychloroquine for COVID-19 Sales by Region: 2027-2032
- 5.3 Global Hydroxychloroquine for COVID-19 Revenue by Region: 2021-2032
- 5.3.1 Global Hydroxychloroquine for COVID-19 Revenue by Region: 2021-2026
- 5.3.2 Global Hydroxychloroquine for COVID-19 Revenue by Region: 2027-2032
- 5.4 North America Hydroxychloroquine for COVID-19 Market Facts & Figures by Country
- 5.4.1 North America Hydroxychloroquine for COVID-19 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hydroxychloroquine for COVID-19 Sales by Country (2021-2032)
- 5.4.3 North America Hydroxychloroquine for COVID-19 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Hydroxychloroquine for COVID-19 Market Facts & Figures by Country
- 5.5.1 Europe Hydroxychloroquine for COVID-19 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hydroxychloroquine for COVID-19 Sales by Country (2021-2032)
- 5.5.3 Europe Hydroxychloroquine for COVID-19 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Hydroxychloroquine for COVID-19 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hydroxychloroquine for COVID-19 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hydroxychloroquine for COVID-19 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hydroxychloroquine for COVID-19 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hydroxychloroquine for COVID-19 Market Facts & Figures by Country
- 5.7.1 South America Hydroxychloroquine for COVID-19 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hydroxychloroquine for COVID-19 Sales by Country (2021-2032)
- 5.7.3 South America Hydroxychloroquine for COVID-19 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Hydroxychloroquine for COVID-19 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hydroxychloroquine for COVID-19 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hydroxychloroquine for COVID-19 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hydroxychloroquine for COVID-19 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Hydroxychloroquine for COVID-19 Sales by Type (2021-2032)
- 6.1.1 Global Hydroxychloroquine for COVID-19 Sales by Type (2021-2032) & (Tons)
- 6.1.2 Global Hydroxychloroquine for COVID-19 Sales Market Share by Type (2021-2032)
- 6.2 Global Hydroxychloroquine for COVID-19 Revenue by Type (2021-2032)
- 6.2.1 Global Hydroxychloroquine for COVID-19 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hydroxychloroquine for COVID-19 Revenue Market Share by Type (2021-2032)
- 6.3 Global Hydroxychloroquine for COVID-19 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hydroxychloroquine for COVID-19 Sales by Application (2021-2032)
- 7.1.1 Global Hydroxychloroquine for COVID-19 Sales by Application (2021-2032) & (Tons)
- 7.1.2 Global Hydroxychloroquine for COVID-19 Sales Market Share by Application (2021-2032)
- 7.2 Global Hydroxychloroquine for COVID-19 Revenue by Application (2021-2032)
- 7.2.1 Global Hydroxychloroquine for COVID-19 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hydroxychloroquine for COVID-19 Revenue Market Share by Application (2021-2032)
- 7.3 Global Hydroxychloroquine for COVID-19 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hydroxychloroquine for COVID-19 Value Chain Analysis
- 8.1.1 Hydroxychloroquine for COVID-19 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hydroxychloroquine for COVID-19 Production Mode & Process
- 8.2 Hydroxychloroquine for COVID-19 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hydroxychloroquine for COVID-19 Distributors
- 8.2.3 Hydroxychloroquine for COVID-19 Customers
9 Global Hydroxychloroquine for COVID-19 Analyzing Market Dynamics
- 9.1 Hydroxychloroquine for COVID-19 Industry Trends
- 9.2 Hydroxychloroquine for COVID-19 Industry Drivers
- 9.3 Hydroxychloroquine for COVID-19 Industry Opportunities and Challenges
- 9.4 Hydroxychloroquine for COVID-19 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst